Brief: Chemomab Therapeutics Q4 EPS USD 0.013
07/03/2024 12:03
Mar 7 (Reuters) - Chemomab Therapeutics Q4 EPS USD 0.013. * Q4 pretax profit USD 3.417 million * Q4 operating expenses USD 3.848 million * Q4 net income USD 3.417 million
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update